Search

Your search keyword '"Wolpin, B"' showing total 111 results

Search Constraints

Start Over You searched for: Author "Wolpin, B" Remove constraint Author: "Wolpin, B"
111 results on '"Wolpin, B"'

Search Results

1. Survival and time off chemotherapy after locoregional therapy for metastatic pancreas cancer

6. Dapagliflozin and cardiovascular outcomes in type 2 diabetes

7. Central adiposity, obesity during early adulthood, and pancreatic cancer mortality in a pooled analysis of cohort studies

8. Composition, spatial characteristics, and prognostic significance of myeloid cell infiltration in pancreatic cancer

10. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

11. P86.08 Phase 2 Study of Zenocutuzumab (MCLA-128), a Bispecific HER2/HER3 Antibody in NRG1 Fusion-Positive Advanced Solid Tumors

14. Hepcidin-regulating Iron-metabolism Genes and Pancreatic Ductal Adenocarcinoma: A Pathway Analysis of Genome-wide Association Studies

15. Étude de phase II « basket » évaluant l’efficacité de l’anticorps monoclonal bispécifique anti-HER2/HER3 MCLA-128 chez les patients atteints de tumeurs solides avancées présentant un réarrangement NRG1

16. Tissue of origin dictates branched-chain amino acid metabolism in mutant Kras-driven cancers

17. Association between telomere length and risk of cancer and non-neoplastic diseases: A Mendelian randomization study

18. Association between telomere length and risk of cancer and non-neoplastic diseases a mendelian randomization study

19. Association Between Telomere Length and Risk of Cancer and Non-Neoplastic Diseases: A Mendelian Randomization Study

20. Association between telomere length and risk of cancer and non-neoplastic diseases a mendelian randomization study

21. Phase Ib study of PF-04136309 (an oral CCR2 inhibitor) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic adenocarcinoma

22. Novel pancreatic cancer susceptibility loci discovered through genome-wild association studies

23. Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer

24. Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer

25. Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody–drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer

27. Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33

28. Diabetes and risk of pancreatic cancer : a pooled analysis from the pancreatic cancer cohort consortium

32. Global, multicenter, open-label, randomized phase II trial comparing gemcitabine (G) with. G plus AGS-1C4D4 (A) in patients (pts) with metastatic pancreatic cancer (mPC).

42. Prospective study of predictors of vitamin D status and survival in patients with colorectal cancer.

46. Identifying regulators of aberrant stem cell and differentiation activity in colorectal cancer using a dual endogenous reporter system.

47. Utilizing a dual endogenous reporter system to identify functional regulators of aberrant stem cell and differentiation activity in colorectal cancer.

49. The age-dependent association of risk factors with pancreatic cancer.

50. Retrospective Case Series Analysis of RAF Family Alterations in Pancreatic Cancer: Real-World Outcomes From Targeted and Standard Therapies.

Catalog

Books, media, physical & digital resources